Monoclonal antibodies as cancer therapeutics

Recent Patents on Biotechnology

Volumn 6, Issue 1, 2012, Pages 45-56

  Elloumi, Jihene ^a   Jellali, Karim ^a   Jemel, Ikram ^a   Aifa, Sami ^a  

^a UNIVERSITY OF SFAX   (Tunisia)

Author keywords

Alemtuzumab; Bevacizumab; Brentuximab; Cetuximab; Combinatory; Gemtuzumumab; Ibritumumab; Immunotherapy; Ipilimumab; Neoplasms; Nimutuzumab; Ofamumumab; Panitumumab; Patents; Retuximab; Tozutumumab; Trastuzumab; United States Food and Drug Administration

Indexed keywords

DISEASES; EFFICIENCY; PATENTS AND INVENTIONS; RADIOTHERAPY; SURFACE PLASMON RESONANCE;

ALEMTUZUMAB; BEVACIZUMAB; BRENTUXIMAB; CETUXIMAB; COMBINATORY; GEMTUZUMUMAB; IBRITUMUMAB; IMMUNOTHERAPY; IPILIMUMAB; NEOPLASM; NIMUTUZUMAB; OFAMUMUMAB; PANITUMUMAB; PATENT; RETUXIMAB; TOZUTUMUMAB; TRASTUZUMAB; UNITED STATES FOOD AND DRUG ADMINISTRATIONS;

MONOCLONAL ANTIBODIES;

2F2; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUDARABINE; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; HP67 6; IBRITUMOMAB TIUXETAN; IDEX C2B8; IPILIMUMAB; IRINOTECAN; MDX 101; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; NIMOTUZUMAB; OFATUMUMAB; OXALIPLATIN; PANITUMUMAB; PIRARUBICIN; PREDNISOLONE; RITUXIMAB; TEHRACIM HR3; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE;

ACNE; ACUTE GRANULOCYTIC LEUKEMIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LEUKEMIA; B CELL LYMPHOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EPITHELIUM TUMOR; ESOPHAGUS CANCER; FOLLICULAR LYMPHOMA; GENE MUTATION; GLIOBLASTOMA; GRAFT REJECTION; HEAD AND NECK CARCINOMA; HEART DISEASE; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; IMMUNE DEFICIENCY; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; ONCOGENE K RAS; OPPORTUNISTIC INFECTION; PANCREAS CANCER; PANCYTOPENIA; PATENT; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; THROMBOCYTOPENIA; THYROID DISEASE; TUMOR LYSIS SYNDROME; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VEIN OCCLUSION;

EID: 84858324585     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/187220812799789190     Document Type: Review

References (161)

1. von Behring E, Kitasato S. [The mechanism of diphtheria immunity and tetanus immunity in animals. 1890]. Mol Immunol 1991; 28: 1317, 1319-20.
2. Tonegawa S, Brack C, Hozumi N, Pirrotta V. Organization of immunoglobulin genes. Cold Spring Harb Symp Quant Biol 1978; 42: 921-31.
3. Seidman JG, Leder P. The arrangement and rearrangement of antibody genes. Nature 1978; 276: 790-5.
4. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
5. Desgranges C. Monoclonal antibodies and therapeutics. Pathologie Biologie 2004; 52: 351-364.
6. Vaughan TJ, Williams AJ, Pritchard K et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol. 1996; 14: 309-14.
7. Russell ND, Corvalan JR, Gallo ML, Davis CG, Pirofski L. Production of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infect Immun 2000; 68: 1820-6.
8. Smith K, Garman L, Wrammert J et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 2009; 4: 372-84.
9. Walker LM, Phogat SK, Chan-Hui PY et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326: 285-9.
10. Yu Y, Lee P, Ke Y et al. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS One 2010; 5: 9072.
11. Simon S. Cross. The molecular pathology of new anti-cancer agents. Current Diagnostic Pathology 2005; 11: 329-339.
12. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
13. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306: 517-22.
14. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005; 54: 11-29.
15. An Z. Monoclonal antibodies-a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 2010; 1: 319-30.
16. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005; 54: 11-29.
17. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984; 312: 643-6.
18. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81: 6851-5.
19. Faulds D, Sorkin EM. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994; 48: 583-98.
20. Riechmann L, Clark M, Waldmann H and Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
21. Carter P, Presta L, Gorman CM et al. Humanization of an antip185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-4289.
22. Presta LG, Lahr SJ, Shields RL et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623-2632.
23. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature 1986; 321: 522-5.
24. Hale G, Dyer MJ, Clark MR et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394-9.
25. Brown PS, Parenteau GL, Dirbas FM et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci U S A. 1991; 88: 2663-7.
26. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321(6069): 522-5.
27. Tempest PR, Bremner P, Lambert M et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (N Y) 1991; 9: 266-71.
28. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003; 9: 129-134.
29. Morrison SL, Canfield S, Porter S, Tan LK, Tao MH, Wims LA. Production and characterization of genetically engineered antibody molecules. Clin Chem 1988; 34: 1668-75.
30. Rapley R. The biotechnology and applications of antibody engineering. Mol Biotechnol 1995; 3: 139-54.
31. Costa AR, Rodrigues ME, Henriques M, Azeredo J, Oliveira R. Guidelines to cell engineering for monoclonal antibody production. Eur J Pharm Biopharm 2010; 74: 127-38.
32. Williams JC, Ulrich RD, Kari JM, Csaba. Development of masked therapeutic antibodies to limit off-target effects: application to antiegfr antibodies. US20110178279, 2011.
33. Pavlou AK, Belsey MJ. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 2005; 59: 389-96.
34. Teillaud JL. Qu'est-ce qu'une biothérapie? L'exemple des anticorps monoclonaux. Presse Med 2009; 38: 825-831.
35. FitzGerald DJ, Kreitman R, Wilson W, Squires D, Pastan I. Recombinant immunotoxins for treating cancer. Int J Med Microbiol 2004; 293: 577-82.
36. Di Paolo C, Willuda J, Kubetzko S et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion moleculespecific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003; 9(7): 2837-48.
37. Milenic DE, Brechbiel MW. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther 2004; 3(4): 361-70.
38. Smith-Jones PM, Solit DB. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. Methods Enzymol 2004; 386: 262-75.
39. DeNardo GL, O'Donnell RT, Kroger LA et al. Strategies for developing effective radioimmunotherapy for solid tumors. Clin Cancer Res 1999; 5: 3219s-3223s.
40. Juweid M, DeNardo GL, Graham M, Vose J. Radioimmunotherapy: a novel treatment modality for B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2003; 18: 673-4.
41. DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5: 533-41.
42. Francis RJ, Sharma SK, Springer C et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 2002; 87: 600-607.
43. Smith AL, Nicolaou KC. The enediyne antibiotics. J Med Chem. 1996; 39: 2103-17.
44. Pamela A, Willner TD, Hellström KE. Site-directed delivery of anthracyclines for treatment of cancer Drug Development Research Volume 1995; 34: 196-209.
45. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 1997; 118: 153-60.
46. Krauss WC, Park JW, Kirpotin DB, Hong K, Benz CC. Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. Breast Dis 2000; 11: 113-124.
47. Cohen S. the receptor for epidermal growth factor functions as a tyrosyl-specific kinase. Prog Nucleic Acid Res Mol Biol 1983; 29: 245-7.
48. Hamid O. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. J Am Pharm Assoc 2004; 44: 52-8.
49. Aifa S, Rebai A. ErbB antagonists patenting: "playing chess with cancer". Recent Pat Biotechnol. 2008; 2: 181-7.
50. Chamuleau ME, van de Loosdrecht AA, Huijgens PC. Monoclonal antibody therapy in haematological malignancies. Curr Clin Pharmacol 2010; 5: 148-59.
51. Buggins AG, Mufti GJ, Salisbury J et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100: 1715-20.
52. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003; 101: 1422-9.
53. Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA. "Expression of CD52 in peripheral T-cell lymphoma". Haematologica 2007; 92: 566-7.
54. Hernández-Caselles T, Martínez-Esparza M, Pérez-Oliva AB et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol 2006; 79: 46-58.
55. Garnache-Ottou F, Chaperot L, Biichle S et al. "Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells". Blood 2005; 105: 1256-64.
56. Rider DA, Havenith CE, De Ridder R et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fcdependent effector activity. Cancer Research 2007; 67: 9945-9953.
57. Gorczyca W, Tsang P, Liu Z et al. CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis. Int J Onco 2003; 22: 319-24.
58. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7: 445-50.
59. Ribas A, Hanson DC, Noe DA et al. Tremelimumab (CP-675, 206), a Cytotoxic T Lymphocyte-Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer. The Oncologist 2007; 12: 873-883.
60. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic TLymphocyte-Associated Antigen 4. Journal of Clinical Oncology 2006: 24; 283-2289.
61. Baeuerle PA, and Gires O. British EpCAM (CD326) finding its role in cancer Journal of Cancer 2007; 96: 417-423.
62. Gottlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G. The epithelial cell surface antigen 17-1A, a target for antibodymediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986; 38: 47-53.
63. Osta WA, Yian C, Mikhitarian K et al. EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy. Cancer Res 2004: 64; 5818.
64. Kraft A, Weindel K, Ochs A et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999: 85; 178-187.
65. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
66. Nakamura Y. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker. US2011/0076280 A1, 2011.
67. Bubendorf L., Bloch M. Kcnma1 as a therapeutic target in cancer treatment. US20070292528, 2007.
68. Johnston J., Burrows J., Kelvin A. Dub3 as a cancer therapy target. US2009/0208446, 2009.
69. Mendelsohn J, Kawamoto T, Sato G, Sato JD. Hybrid Cell Lines That Produce Monoclonal Antibodies To Epidermal Growth Factor Receptor. US 4943533, 1990.
70. Shitara K, Yuki S, Yoshida M et al. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wildtype KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Invest New Drugs 2010. DOI 10.1007/s10637-010-9615-z
71. Moosmann N, von Weikersthal LF, Vehling-Kaiser U et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. J Clin Oncol 2011; 29: 1050-8.
72. Sartore-Bianchi A, Bencardino K, Cassingena A et al. Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treat Rev 2010; 36: S1-5.
73. Nguyen A, Hoang V, Laquer V, Kelly KM. Angiogenesis in cutaneous disease: part I. J. Am. Acad. Dermatol 2009: 61: 921-42.
74. Kucherlapati R, Jakobovits A. Method of making transgenic mice lacking endogenous heavy chains. US5939598, 1999.
75. Kucherlapati R, Jakobovits A, Klapholz S, Brenner DG, Capon DJ. Generation of xenogeneic antibodies. US 2004/0093622 A1, 2004.
76. US Food and Drug Administartion. Cetuximab (Erbitux) and Panitumumab (Vectibix) Available at: http://www.fda.gov/AboutFDA/ CentersOffices/CDER/ucm172905.htm (Accessed on: July 17, 2009).
77. Amado RG, Wolf M, Peeters M et al. Wild-Type KRAS Is Required for Panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008; 26: 1626-1634.
78. Raffaele A, Michele C, Domenico C, Gaetano N, Alberto A, Salvatore DP. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy 2010; 10: 499-505.
79. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3: 71-81.
80. Cristina Maria Mateo de Acosta del Rio, Rolando Perez Rodriguez, Ernesto Moreno Frias. Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGFR); diagnostic and therapeutic Use: US5891996, 1997.
81. Ramos TC, Parada AC, Escobar NI. h-R3. Drugs Future 2003; 28 (suppl 9): 847-853.
82. Allan DG. Nimotuzumab: Evidence of clinical benefit without rash. Oncologist 2005; 10: 760-761.
83. Pendharkar D, Gupta S, Pal MK, Hakim S, Rashid T. Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 (nimotuzumab) with chemotherapy_A study of toxicity profile and tolerance. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25: 141-51.
84. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30: 39-50.
85. Vecchione L. Novel investigational drugs for gastric cancer. Expert Opin Investig Drugs 2009; 18: 945-55.
86. Carter, P.J., Presta, L.G. Immunoglobulin variants. US5821337, 1998.
87. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002; 29: 29-37.
88. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-80.
89. Kute T; Lack CM, Willingham M et al. Development of herceptin resistance in breast cancer cells. Cytometry 2004; 57A: 86-93.
90. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience". Journal of Clinical Oncology 2002; 20: 1215-1221.
91. Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. US5736137, 1998.
92. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
93. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998; 6: 195-7.
94. Flynn JM, Byrd, JC. Campath-1H monoclonal antibody therapy. Current Opinion in Oncology 2000; 12: 574-581.
95. Andreas A. Molecularly Targeted Therapies for Dysimmune Neuropathies. Mol Med. 2009; 15: 283-287.
96. Anderson DR, Hanna N, Newman RA, Reff ME., Rastetter WH. Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B cell lymphoma. US 6399061, 1995.
97. Adams GP and Weiner LM. Monoclonal antibody therapy of cancer. Nature biotechnology 2005; 23: 1147-1157.
98. Witzig TE, Flinn IW, Gordon LI. et al. Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 2002; 20: 3262-3269.
99. Ahmed S http://informahealthcare.com/action/showPopup?citid= citart1&id=AF0001&doi=10.3109/10428191003793366
100. Winter JNhttp://informahealthcare.com/action/showPopup?citid=citart1&i d=AF0001&doi=10.3109/10428191003793366
101. Gordon LI http://informahealthcare.com/action/showPopup?citid=citart1&id= AF0001&doi=10.3109/10428191003793366
102. Evens A M. Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: cur rent status and future applications. Leukemia & Lymphoma 2010; 51: 1163-1177.
103. Hashino S, Morioka M, Irie T et al. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma. Int J Lab Hematol 2008; 30: 292-9.
104. Witzig TE, Gordon LI., Cabanillas F et al. Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 2002; 20: 2453-2463.
105. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-85.
106. Kaminski MS, Butchko GM., Glenn SD, Wahl RL. Radioimmunotherapy of lymphoma using anti-CD20. US 5595721, 1997.
107. Gopal AK, Rajendran JG, Petersdorf SH et al. High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158-3162.
108. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Yibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med 2007: 48: 1767-76.
109. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104: 1793-1800.
110. Teeling J, Ruuls S, Glennie M, van de Winkel JGJ, Parren P, Petersen J, Baadsgaard O, Huang H. Human monoclonal antibodies against CD20. US 2004/0167319 A1, 2004.
111. O'Brien S, Osterborg A. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2010; 10: 361-8.
112. Us Food and Drug Administration. Ofatumumab Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm188221. htm (accessed on May 29, 2009).
113. Herman Waldmann, Michael R. Clark, Gregory P. Winter, Lutz Riechmann. Antibodies to the antigen campath-1. US 5846534, 1998.
114. Claire E. Dearden, Matutes E, and Catovsky D. Alemtuzumab in TCell Malignancies. Medical Oncology 2002; 19: S27-S32.
115. Tzakis AG, Kato T, Nishida S et al. Preliminary experience with Campath 1H (C1H) in intestinal and liver transplantation. Transplantation. 2003; 75: 1227-1231.
116. Stuart FP, Leventhal JR, Kaufman DB et al. Alemtuzumab facilitates prednisone free immunosuppression in kidney transplant recipients with no early rejection. Am J Transplant. 2002; 2: 397.
117. Demko S http://theoncologist.alphamedpress.org/content/13/2/ 167.short-aff-1#aff-1, Summers J, Keegan P http://theoncologist. alphamedpress.org/content/13/2/167.short-aff-1#aff-1and Pazdur R. FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia. The Oncologist February 2008; 13: 2 167-2174.
118. Riechmann L, Clark M, Waldmann H and Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
119. Hansel TT, Kropshofer HD, Singer T, Mitchell JA and George AJT. The safety and side effects of monoclonal antibodies. Nature Reviews Drug Discovery 2010; 9; 325-338.
120. Walter RB, Gooley TA, van der Velden VH et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109: 4168-70.
121. Kuntsmann MP, Hollander I, Hamann P. Method for the preparation of substantiality monomeric calicheamicin derivative/carrter conjugates. US5712374, 1998.
122. Zwaan CM, Reinhardt D, Corbacioglu S et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/ refractory acute myeloid leukemia treated on compassionate-use basis. Blood 2003; 101: 3868-3871.
123. Giles FJ, Kantarjian HM, Kornblau SM et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92: 406-13.
124. Bross PF, Beitz J, Chewn G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490-6.
125. Mylotarg (gemtuzumab ozogamicin): Market withdrawal. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm216458.htm (Accessed on June 21, 2010).
126. Peter D. Senter, Svetlana O. Doronina, Brian E. Toki Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease US7659241, 2010.
127. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-21.
128. US Food and Drug Administration. Oncologic drugs advisory committee meeting announcement. Available at: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm259804.ht m (Accessed on: July 14, 2011).
129. Hanson DCh, Neveu MJ, Mueller EE, Hanke JH, Gilman SCh, Davis CG, Corvalan JR. Human monoclonal antibodies to CTLA-4. US 2004/0228858 A1, 2004.
130. Mori T. Ipilimumab, a new molecular targeted therapy of malignant neoplastic disease Gan To Kagaku Ryoho 2011; 38: 31-5.
131. Bianco R, Gelardi T, Garofalo S, Rosa R, Tortora G. In: Reddy LH, Couvreur P Human Press. Macromolecular Anticancer Therapeutics. Springer 2010: pp. 522.
132. US Food and Drug Administration. Ipilimumab. Avalable at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm248478. htm (Accessed on: March 25, 2011).
133. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2008; 30: 643-72.
134. Poust J. Targeting metastatic melanoma. Am J Health Syst Pharm 2008; 65: S9-S15.
135. Hodi FS, O'Day SJ, McDermott DF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
136. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. The Oncologist 2007; 12: 443-50.
137. Patricia R, Redding W, Goldstein NI, Maplewood N.J. Methods of use of chimerized, humanized, and single chain antibodies specific to vegf receptor. US5840301, 1998.
138. Rivera Fernando, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncologica 2008; 47: 9-19.
139. Okines A, Cunningham D. Current perspective: bevacizumab in colorectal cancer-a time for reappraisal? Eur J Cancer. 2009; 45: 2452-61.
140. US Food and Drug Administration. Cder: notice of initiation of disqualification proceedings and opportunity to explain (nidpoe). Available at http://www.fda.gov/RegulatoryInformation/FOI/ ElectronicReadingRoom/ ucm105756.htm (Assessed on September 22, 2004).
141. Us Food and Drug Administration. Bevacizumab. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm129230. htm (Accessed on: Februry 22, 2008).
142. Us Food and Drug "FDA begins process to remove breast cancer indication from Avastin label". Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm237172.htm (Accessed on: December 16, 2010).
143. Us Food and Drug Administration. Avastin (bevacizumab) Information. Availabale at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm193900.htm (Accessed on: June 29, 2011)
144. Us Food and Drug Administration. Bevacizumab (Avastin) in Combination with Interferon Alfa. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm176025. htm (Accessed on: July 31, 2009)
145. Us Food and Drug Administration. Bevacizumab Injection. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ ucm149364.htm (Accessed on: May 5, 2009).
146. Schultes BC, Mass A, Nicodemus CF, Mass C, Noujaim AA, Madiyalakan R. Combination therapy for treating disease. US8038994 B2, 2011.
147. Egloff AM and Grandis JR. Improving response rates to EGFRtargeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors. Journal of Oncology 2009; doi:10.1155/ 2009/896407.
148. Nahta R; Esteval FJ. HER-2-targeted therapy-lessons learned and future directions. Clinical Cancer Research 2003; 9: 5078-5048.
149. Pegram MD, Pienkowski T, Northfelt DW et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96: 759-69.
150. Cho HM, Rosenblatt JD, Kang YS et al. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther 2005; 4: 956-67.
151. Yang QY, Shen D, Sai K, Mu YG, Jiang XB, Zhang XH, Chen ZP. Nimotuzumab in combination with chemotherapy for patients with malignant gliomas. Zhonghua Zhong Liu Za Zhi 2011; 33: 232-5.
152. Margit W, Jens Bo Rode H, Anja Hoeg, Keith M. Method for the treatment of cancer. WO 2010043582 A1, 2010.
153. Us Food and Drug Administration. FDA Approves First Angiogenesis Inhibitor to Treat Colorectal Cancer. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 2004/ucm108252.htm (Accessed on, February 26, 2004).
154. Us Food and Drug Administration. Avastin (bevacizumab) Information. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm193900. htm (Accessed on: June 29, 2011).
155. Hara T, Goto N, Kitagawa JI et al. A phase II study of Rituximab combined with THP-COP regimen as a first-line therapy for patients with indolent B-cell lymphoma. Leuk Lymphoma. 2011 doi:10.3109/10428194.2011.606383.
156. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM. & Chen L Immunostimulatory monoclonal antibodies for cancer therapy. Nature Reviews Cancer 2007; 7: 95-106.
157. Xie J, Murone M, Luoh SM et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391: 90-2.
158. Roger Monier. Usage des anticorps monoclonaux en thérapeutique. Conclusion. C. R. Biologies 2006; 329: 263-264.
159. Summer B and Gao J. Theranostic nanomedecine in cancer. Nanomedicine 2008; 3: 137-140.
160. Gunn HD. Tissue targeted antigenic activation of the immune response to cancers. US 2011/0195093 A1, 2011.
161. Szalay AA, Timiryasova T, Yu YA, Zhang Q. Microorganisms for therapy. US8021662, 2011.